« previous next »
Pages: [1]

Author Topic: (Abst.) Long-term disease activity and disability progression in RRMS patients on Tysabri  (Read 124 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9839
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Long-term disease activity and disability progression in RRMS patients on Tysabri
« on: June 08, 2019, 09:32:13 am »
Not much information about just how the patients taking Tysabri (or other MS drugs) are doing over time but this research concludes:


Quote
When taking into account early inflammation and the impact of natalizumab on disease activity during the initial treatment phase, a higher than expected proportion of patients showed disability progression.


From PubMed, June 8, 2019--"Long-term disease activity and disability progression in RRMS patients on natalizumab" by researchers in Amsterdam, including two who are well known in MS research--Barkhof, Uitdehaag:


https://www.ncbi.nlm.nih.gov/pubmed/31174043
« Last Edit: June 08, 2019, 09:34:28 am by agate »
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics